Trastuzumab vedotin

维曲妥珠单抗

Report date: 2024/07/03 15:53:59

Base Information

Drug NameTrastuzumab vedotin
Drug Alias NameMRG-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-HER2Tubulin inhibitorsTubulin polymerisation inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Miracogen Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Miracogen Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[7] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungBile Duct NeoplasmsBiliary Tract Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A